Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Study Confirms Benefits of Lecanemab in Early Alzheimer Disease

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form